PRKCA and neoplasm: By discovering the mechanism in this signalling transduction pathway, we propose that a combined treatment of TG2 inhibition with the inhibition of key signalling targets e.g. PKCα could be more promising therapeutic approach for the treatment of S100A4 and TG2 containing tumours.